Bio-Rad Laboratories (NYSE:BIO.B) Hits New 1-Year High – Should You Buy?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) hit a new 52-week high during trading on Monday. The company traded as high as $389.98 and last traded at $389.98, with a volume of 76 shares changing hands. The stock had previously closed at $379.50.

Bio-Rad Laboratories Trading Up 2.8%

The stock has a market capitalization of $10.43 billion, a PE ratio of 10.27 and a beta of 0.96. The company’s 50 day moving average price is $367.51 and its two-hundred day moving average price is $312.98. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO.B) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $2.65 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. The company had revenue of $656.40 million during the quarter.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops and manufactures products for life science research and clinical diagnostics. Founded in 1952, the company serves research institutions, biotechnology and pharmaceutical companies, clinical laboratories, hospitals and other customers around the world.

Its life science business supplies instruments, reagents and software used in areas such as gene expression, protein analysis, cell biology and genomics. Its offerings include PCR and digital PCR systems, electrophoresis products and tools for protein purification and analysis.

Bio-Rad’s clinical diagnostics business provides testing systems, reagents and quality-control products for laboratories.